Calidi Biotherapeutics, Inc.
CLDI · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -90% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | – | – | -508.9% | 79.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -55,551.1% | -2,104.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -56,504.4% | -2,435% |
| EPS Diluted | -35.7 | -207.61 | -358.8 | 14.16 |
| % Growth | 82.8% | 42.1% | -2,633.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |